IL267191A - - Google Patents

Info

Publication number
IL267191A
IL267191A IL26719119A IL26719119A IL267191A IL 267191 A IL267191 A IL 267191A IL 26719119 A IL26719119 A IL 26719119A IL 26719119 A IL26719119 A IL 26719119A IL 267191 A IL267191 A IL 267191A
Authority
IL
Israel
Application number
IL26719119A
Other languages
Hebrew (he)
Other versions
IL267191B2 (en
IL267191B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL267191A publication Critical patent/IL267191A/he
Publication of IL267191B1 publication Critical patent/IL267191B1/en
Publication of IL267191B2 publication Critical patent/IL267191B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL267191A 2016-12-14 2019-06-10 Use of a carbamate compound to prevent, relieve or treat tremors or tremor syndrome IL267191B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14
PCT/KR2017/014743 WO2018111009A1 (ko) 2016-12-14 2017-12-14 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
IL267191A true IL267191A (enExample) 2019-07-31
IL267191B1 IL267191B1 (en) 2023-01-01
IL267191B2 IL267191B2 (en) 2023-05-01

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267191A IL267191B2 (en) 2016-12-14 2019-06-10 Use of a carbamate compound to prevent, relieve or treat tremors or tremor syndrome

Country Status (14)

Country Link
US (1) US11033531B2 (enExample)
EP (1) EP3556364B1 (enExample)
JP (1) JP7086076B2 (enExample)
KR (1) KR102635941B1 (enExample)
CN (1) CN110267657B (enExample)
AU (1) AU2017374459B2 (enExample)
CA (1) CA3046300A1 (enExample)
CL (1) CL2019001623A1 (enExample)
ES (1) ES3039979T3 (enExample)
IL (1) IL267191B2 (enExample)
MX (1) MX391363B (enExample)
MY (1) MY198417A (enExample)
WO (1) WO2018111009A1 (enExample)
ZA (1) ZA201903749B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019098626A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
JP7408643B2 (ja) * 2018-09-21 2024-01-05 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2014142518A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating a movement disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530694A (ja) 2004-03-29 2007-11-01 メルク エンド カムパニー インコーポレーテッド ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
CN101657194B (zh) * 2007-03-05 2013-10-23 Indus生物技术私人有限公司 包含葫芦巴碱和4-羟基异亮氨酸的药物组合物及其方法
CN102803233B (zh) * 2009-06-22 2017-03-01 爱思开生物制药株式会社 制备氨基甲酸(r)‑1‑芳基‑2‑四唑基‑乙酯的方法
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2014142518A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating a movement disorder

Also Published As

Publication number Publication date
MX391363B (es) 2025-03-21
MX2019006941A (es) 2019-09-06
WO2018111009A1 (ko) 2018-06-21
JP7086076B2 (ja) 2022-06-17
ZA201903749B (en) 2022-01-26
CA3046300A1 (en) 2018-06-21
CN110267657A (zh) 2019-09-20
RU2019121914A3 (enExample) 2021-04-21
IL267191B2 (en) 2023-05-01
KR102635941B1 (ko) 2024-02-13
KR20190087573A (ko) 2019-07-24
EP3556364A4 (en) 2020-06-17
US20190336481A1 (en) 2019-11-07
JP2020502137A (ja) 2020-01-23
AU2017374459A1 (en) 2019-07-04
CL2019001623A1 (es) 2019-08-23
MY198417A (en) 2023-08-29
US11033531B2 (en) 2021-06-15
RU2019121914A (ru) 2021-01-15
CN110267657B (zh) 2022-12-13
EP3556364B1 (en) 2025-08-27
ES3039979T3 (en) 2025-10-28
IL267191B1 (en) 2023-01-01
EP3556364A1 (en) 2019-10-23
AU2017374459B2 (en) 2023-04-27
BR112019012000A2 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
BR112019009191A2 (enExample)
BR112019002665A2 (enExample)
BR112019008128A2 (enExample)
BR112019001685A2 (enExample)
BR112019000402A2 (enExample)
IL267191A (enExample)
BR202016008885U2 (enExample)
BR202016005183U2 (enExample)
CN303537333S (enExample)
CN303538864S (enExample)
CN303536236S (enExample)
CN303536241S (enExample)
CN303536258S (enExample)
CN303536391S (enExample)
CN303536426S (enExample)
CN303536494S (enExample)
CN303536529S (enExample)
CN303536541S (enExample)
CN303536593S (enExample)
CN303536622S (enExample)
CN303536638S (enExample)
CN303537266S (enExample)
CN303537289S (enExample)
CN303537328S (enExample)
CN303536206S (enExample)